DOCSLIB.ORG

A Third Locus for Dominant Optic Atrophy on Chromosome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Third Locus for Dominant Optic Atrophy on Chromosome 1of4 ELECTRONIC LETTER J Med Genet: first published as 10.1136/jmg.2004.025502 on 5 January 2005. Downloaded from A third locus for dominant optic atrophy on chromosome 22q F Barbet, S Hakiki, C Orssaud, S Gerber, I Perrault, S Hanein, D Ducroq, J-L Dufier, A Munnich, J Kaplan, J-M Rozet ............................................................................................................................... J Med Genet 2005;42:e1 (http://www.jmedgenet.com/cgi/content/full/42/1/e1). doi: 10.1136/jmg.2004.025502 utosomal dominant optic atrophy (ADOA) is the most common form of autosomally inherited optic neuro- Key points pathy, with an estimated prevalence of 1:50 000 in A 1 2 most populations, though it can reach 1:10 000 in Denmark. N Autosomal dominant optic atrophies (ADOA) are by The disease typically presents in childhood with variable far the most common mendelian cause of primary bilateral slow visual loss, temporal optic nerve pallor, centro- hereditary optic neuropathy. A major locus has been caecal visual field scotoma, and abnormalities of colour mapped to chromosome 3q28–q29 and the OPA1 vision.3 In most families, the disease is accounted for by gene identified. The penetrance of the disease mutations in the OPA1 gene, at the OPA1 locus on accounted for by mutations in this gene is reported to chromosome 3q28–q29 (MIM165500). The penetrance of be highly variable. A second locus, OPA4, has been the OPA1 disease is highly variable as well as its age of onset, mapped on chromosome 18q12.2–q12.3 in a family even within the same family. whose phenotype was similar to that of OPA1 patients. Some ADOA families have been shown to exclude linkage N to the OPA1 locus.45 In 1999, the genetic study of a large We report the mapping of a third locus of ADOA, family whose phenotype was similar to the OPA1 phenotype, OPA5, on chromosome 22q12.1–q13.1 in two unre- allowed the mapping of a second ADOA locus on chromo- lated families of French origin. The phenotype of some 18q12.2–q12.3 (OPA4, MIM605293).5 To date, no report affected patients of the two families was similar to that has confirmed this localisation and the disease gene is still of patients harbouring OPA1 mutations. unknown. N The OPA5 locus lies in a 10.4 Mb interval flanked by Here we report the mapping of a third ADOA locus on the D22S1148 and D22S283 loci. To date, 73 known chromosome 22q12.1–q13.1 (OPA5) in two unrelated genes and as many predicted genes are contained in families affected with a OPA1-like phenotype. this interval. Screening of OSBP2, C22ORF3, HSC20 and HSPC051 failed to identify any mutation. METHODS Patients http://jmg.bmj.com/ Two unrelated multiplex families of French origin affected with autosomal dominant optic atrophy were ascertained automatic sequencer (ABI 3100, Applied Biosystems, Foster through the genetic consultation clinic of the Hoˆpital des City, California, USA). Linkage analyses were carried out Enfants Malades in Paris (family A and family B; fig 1 A and using M-LINK and LINKMAP of the 5.1 version of the B, respectively). All members of each family underwent Linkage program.78All allele frequencies were available from ophthalmological examination including visual acuity mea- the CEPH database. The gene frequency was estimated to be surements, visual field testing, colour vision analysis, ocular 1/1000 and the penetrance of the disease to be 100%. pressure measurement, examination of the fundi, and on September 26, 2021 by guest. Protected copyright. electrophysiological recordings. Blood was collected from all family members and the DNA was purified by phenol- Screening for mutations in candidate genes chloroform extraction. The 14 exons encoding the oxysterol binding protein 2 (OSBP2), the five hypothetical exons of the chromosome 22 open reading frame 3 (C22ORF3), the six exons of the J Linkage analysis Linkage to known ADOA loci was studied in both families. type co-chaperone HSC20 gene, and the two exons of Four markers flanking the OPA1 locus on chromosome 3q28– the ubiquinol-cytochrome c reductase 7.2 kDa complex q29 were chosen from the Ge´ne´thon linkage map on the basis (HSPC051) were amplified using specific primers designed of their informativeness6—AFM308yf1, AFMa300wa5, from intronic sequences close to the intron-exon junctions AFMb043xe9, and AFM254ve1 at the D3S1601, D3S3590, (not shown, available on request). Amplified products were D3S2748, and D3S1311 loci, respectively. For the OPA4 locus, purified by phenol-chloroform extraction, recovered by we selected three markers lying in the genetic interval on ethanol precipitation, and directly sequenced using the Big chromosome 18q12.2–q12.3 as well as two flanking markers: Dye terminator cycle sequencing kit V3 on a 3100 automated AFM147yf2, AFM191vc7, and AFM284ve1 at the D18S1094, sequencer (ABI Prism, Applied Biosystems). D18S450, and D18S472 loci, respectively; and AFMa224wb1 and AFM295xh1 at the D18S1102 and D18S474 loci. RESULTS A 10 cM genome-wide search for the disease causing gene Clinical evaluation was undertaken in family A using fluorescent oligonucleo- We report two unrelated multiplex families of French origin tides flanking the 382 polymorphic markers of the Genescan affected with ADOA. Although the age of onset of the disease Linkage Mapping Set, version II (Perkin Elmer Cetus), under conditions recommended by the manufacturer. Amplified fragments were electrophoresed and analysed on an Abbreviations: ADOA, autosomal dominant optic atrophy www.jmedgenet.com 2of4 Barbet, Hakiki, Orssaud, et al J Med Genet: first published as 10.1136/jmg.2004.025502 on 5 January 2005. Downloaded from Family A Family B I I 1 2 1 2 D22S420 12 8 4 D22S315 2 5 1 D22S1148 8 10 7 D22S1154 5 2 2 D22S1167 4 6 4 II D22S1144 6 4 4 1 2 3 4 5 6 7 8 D22S1163 2 2 4 D22S275 3 8 9 D22S420 4 2 4 2 2 2 4 2 4 4 4 2 5 3 4 2 D22S1150 2 2 3 D22S315 1 1 2 1 1 1 2 1 2 2 1 1 4 9 1 1 D22S1176 3 4 2 D22S1148 11 1 12 1 2 1 12 1 1 1 11 1 1 1 11 1 D22S273 1 2 5 D22S1154 2 5 2 5 2 2 2 5 2 5 2 5 2 2 2 5 D22S280 5 1 7 D22S1167 1 2 2 4 4 4 2 2 2 2 1 2 5 1 2 4 D22S281 1 6 6 D22S1144 7 1 7 1 4 4 7 1 4 1 7 1 3 7 7 1 D22S1158 8 14 8 D22S1163 2 2 4 2 4 2 4 2 1 2 2 2 4 4 4 2 D22S1147 1 5 1 D22S275 8 4 1 1 4 1 1 4 4 4 8 4 1 2 1 1 D22S278 6 2 2 D22S1150 10 2 3 3 2 3 3 2 2 2 10 2 11 3 3 3 D22S283 8 13 15 D22S1176 3 2 4 1 1 3 4 2 5 8 3 2 1 2 4 1 D22S1177 4 5 1 D22S273 1 1 2 2 2 1 2 1 3 1 1 1 2 6 2 2 D22S1156 2 2 2 D22S280 2 1 5 1 7 4 5 1 3 2 2 1 2 4 5 1 D22S281 2 3 3 3 9 5 3 3 6 5 2 3 10 5 3 3 D22S1158 2 10 4 9 10 2 4 10 2 2 2 10 12 2 4 9 D22S1147 1 8 1 1 1 1 1 8 5 1 1 8 2 1 1 1 II D22S278 5 2 4 6 2 2 4 6 2 4 5 2 5 2 4 6 1 2 3 4 D22S283 8 8 8 15 15 3 8 15 1 13 1 8 6 1 8 15 D22S420 2 4 2 8 2 8 2 5 D22S1177 3 1 3 1 1 5 3 1 1 4 2 1 5 4 3 1 D22S315 11 1 2 5 2 5 12 1 D22S1156 2 2 2 6 2 2 2 6 1 6 1 2 2 2 2 6 D22S1148 2 2 8 10 8 10 1 2 D22S1154 2 2 5 2 5 2 3 2 D22S1167 1 2 4 6 4 6 2 2 III D22S1144 4 1 6 4 6 4 1 5 1 2 3 4 5 D22S1163 4 4 2 2 2 2 2 2 D22S275 2 4 3 8 3 8 5 5 D22S420 2 2 4 4 4 4 5 4 5 4 D22S1150 3 2 2 2 2 2 3 3 D22S315 2 1 2 2 2 2 4 1 4 1 D22S1176 1 3 3 4 3 4 3 1 D22S1148 12 2 12 1 12 1 1 11 1 11 D22S273 2 1 1 2 1 2 4 2 D22S1154 2 2 2 2 2 2 2 2 2 2 D22S280 4 1 5 1 5 1 2 4 D22S1167 2 4 2 2 2 2 5 2 5 2 D22S281 5 2 1 6 1 6 1 6 D22S1144 7 4 7 4 7 4 3 7 3 7 D22S1158 5 14 8 14 8 8 8 8 D22S1163 4 4 4 1 4 1 4 4 4 4 D22S1147 6 1 1 5 1 1 1 1 D22S275 1 4 1 4 1 4 1 1 1 1 D22S278 2 4 6 2 6 2 6 2 D22S1150 3 2 3 2 3 2 11 3 11 3 D22S283 12 16 8 13 8 15 8 1 D22S1176 4 1 4 5 4 5 1 4 1 4 D22S1177 3 1 4 5 4 1 4 1 D22S273 2 2 2 3 2 3 2 2 2 2 D22S1156 2 2 2 2 2 2 7 2 D22S280 5 7 5 3 5 3 2 5 2 5 D22S281 3 9 3 6 3 6 10 3 10 3 D22S1158 4 10 4 2 4 2 12 4 12 4 D22S1147 1 1 1 5 1 5 2 1 2 1 III D22S278 4 2 4 2 4 2 5 4 5 4 1 2 3 D22S283 8 15 8 1 8 1 6 8 6 8 D22S420 2 8 2 8 8 2 D22S1177 3 1 3 1 3 1 5 3 5 3 D22S315 11 5 1 2 5 12 D22S1156 2 2 2 1 2 1 2 2 2 6 D22S1148 2 10 2 8 10 1 D22S1154 2 2 2 5 2 3 D22S1167 1 6 2 4 6 2 D22S1144 4 4 1 6 4 1 http://jmg.bmj.com/ D22S1163 4 2 4 2 2 2 D22S275 2 8 4 3 8 5 D22S1150 3 2 2 2 2 3 D22S1176 1 4 3 3 4 3 D22S273 2 2 1 1 2 4 D22S280 4 1 1 5 1 2 D22S281 5 6 2 1 6 1 D22S1158 5 14 14 8 8 8 D22S1147 6 5 1 1 1 1 Figure 1 Haplotype of families A and B at the OPA5 locus on D22S278 2 2 4 6 2 6 D22S283 12 13 16 8 15 8 chromosome 22q12.1–q13.1, respectively.
Load more

Recommended publications
  • Network Medicine Approach for Analysis of Alzheimer's Disease Gene Expression Data
    International Journal of Molecular Sciences Article Network Medicine Approach for Analysis of Alzheimer’s Disease Gene Expression Data David Cohen y, Alexander Pilozzi y and Xudong Huang * Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; [email protected] (D.C.); [email protected] (A.P.) * Correspondence: [email protected]; Tel./Fax: +1-617-724-9778 These authors contributed equally to this work. y Received: 15 November 2019; Accepted: 30 December 2019; Published: 3 January 2020 Abstract: Alzheimer’s disease (AD) is the most widespread diagnosed cause of dementia in the elderly. It is a progressive neurodegenerative disease that causes memory loss as well as other detrimental symptoms that are ultimately fatal. Due to the urgent nature of this disease, and the current lack of success in treatment and prevention, it is vital that different methods and approaches are applied to its study in order to better understand its underlying mechanisms. To this end, we have conducted network-based gene co-expression analysis on data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. By processing and filtering gene expression data taken from the blood samples of subjects with varying disease states and constructing networks based on that data to evaluate gene relationships, we have been able to learn about gene expression correlated with the disease, and we have identified several areas of potential research interest. Keywords: Alzheimer’s disease; network medicine; gene expression; neurodegeneration; neuroinflammation 1. Introduction Alzheimer’s disease (AD) is the most widespread diagnosed cause of dementia in the elderly [1].
    [Show full text]
  • Identification of P.A684V Missense Mutation in the WFS1 Gene As a Frequent Cause of Autosomal Dominant Optic Atrophy and Hearing
    RESEARCH ARTICLE Identification of p.A684V Missense Mutation in the WFS1 Gene as a Frequent Cause of Autosomal Dominant Optic Atrophy and Hearing Impairment Nanna D. Rendtorff,1 Marianne Lodahl,1 Houda Boulahbel,2 Ida R. Johansen,1 Arti Pandya,3 Katherine O. Welch,4 Virginia W. Norris,4 Kathleen S. Arnos,4 Maria Bitner-Glindzicz,5 Sarah B. Emery,6 Marilyn B. Mets,7 Toril Fagerheim,8 Kristina Eriksson,9 Lars Hansen,1 Helene Bruhn,10 Claes M€oller,11 Sture Lindholm,12 Stefan Ensgaard,13 Marci M. Lesperance,6 and Lisbeth Tranebjaerg1,14*,† 1Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine (ICMM), The Panum Institute, University of Copenhagen, Copenhagen, Denmark 2Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark 3Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia 4Department of Biology, Gallaudet University, Washington DC 5UCL Institute of Child Health, London, UK 6Division of Pediatric Otolaryngology, Department of Otolaryngology-Head and Neck Surgery, UniversityofMichiganHealthSystem,AnnArbor,Michigan 7Departments of Ophthalmology and Surgery, Feinberg School of Medicine, Northwestern University, Evanston, Illinois 8Division of Child and Adolescent Health, Department of Medical Genetics, University Hospital of North Norway, Tromsø, Norway 9Department of Ophthalmology, Lundby Hospital, Gothenburg, Sweden 10Division of Metabolic Diseases, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden 11Department of Audiology/Disability Research (SIDR), O¨rebro University, Sweden 12Department of Audiology, County Hospital, Kalmar, Sweden 13Department of Psychiatrics, Stockholm, Sweden 14Department of Audiology, Bispebjerg Hospital, Copenhagen, Denmark Received 19 July 2010; Accepted 2 February 2011 Optic atrophy (OA) and sensorineural hearing loss (SNHL) are these additional eight families.
    [Show full text]
  • Dominant Optic Atrophy
    Lenaers et al. Orphanet Journal of Rare Diseases 2012, 7:46 http://www.ojrd.com/content/7/1/46 REVIEW Open Access Dominant optic atrophy Guy Lenaers1*, Christian Hamel1,2, Cécile Delettre1, Patrizia Amati-Bonneau3,4,5, Vincent Procaccio3,4,5, Dominique Bonneau3,4,5, Pascal Reynier3,4,5 and Dan Milea3,4,5,6 Abstract Definition of the disease: Dominant Optic Atrophy (DOA) is a neuro-ophthalmic condition characterized by a bilateral degeneration of the optic nerves, causing insidious visual loss, typically starting during the first decade of life. The disease affects primary the retinal ganglion cells (RGC) and their axons forming the optic nerve, which transfer the visual information from the photoreceptors to the lateral geniculus in the brain. Epidemiology: The prevalence of the disease varies from 1/10000 in Denmark due to a founder effect, to 1/30000 in the rest of the world. Clinical description: DOA patients usually suffer of moderate visual loss, associated with central or paracentral visual field deficits and color vision defects. The severity of the disease is highly variable, the visual acuity ranging from normal to legal blindness. The ophthalmic examination discloses on fundoscopy isolated optic disc pallor or atrophy, related to the RGC death. About 20% of DOA patients harbour extraocular multi-systemic features, including neurosensory hearing loss, or less commonly chronic progressive external ophthalmoplegia, myopathy, peripheral neuropathy, multiple sclerosis-like illness, spastic paraplegia or cataracts. Aetiology: Two genes (OPA1, OPA3) encoding inner mitochondrial membrane proteins and three loci (OPA4, OPA5, OPA8) are currently known for DOA. Additional loci and genes (OPA2, OPA6 and OPA7) are responsible for X-linked or recessive optic atrophy.
    [Show full text]
  • TIMM8A Gene Translocase of Inner Mitochondrial Membrane 8A
    TIMM8A gene translocase of inner mitochondrial membrane 8A Normal Function The TIMM8A gene provides instructions for making a protein that is found inside mitochondria, which are structures within cells that convert the energy from food into a form that cells can use. Mitochondria have two membranes, an outer membrane and an inner membrane, which are separated by a fluid-filled area called the intermembrane space. The TIMM8A protein is found in the intermembrane space, where it forms a complex (a group of proteins that work together) with a very similar protein called TIMM13. This complex transports other proteins across the intermembrane space to the mitochondrial inner membrane. Health Conditions Related to Genetic Changes Deafness-dystonia-optic neuronopathy syndrome At least 20 mutations in the TIMM8A gene have been found to cause deafness-dystonia- optic neuronopathy (DDON) syndrome. Most of these mutations result in the absence of functional TIMM8A protein inside the mitochondria, which prevents the formation of the TIMM8A/TIMM13 complex. Researchers believe that the lack of this complex leads to abnormal transport of proteins across the intermembrane space, although it is unclear how abnormal protein transport affects the function of the mitochondria and causes the signs and symptoms of DDON syndrome. Some people with DDON syndrome have large DNA deletions that remove the entire TIMM8A gene and one end of a neighboring gene known as BTK. Mutations in the BTK gene cause X-linked agammaglobulinemia (XLA), which is characterized by an increased susceptibility to infections. Individuals with large DNA deletions that include the TIMM8A gene and the BTK gene have the signs and symptoms of both DDON syndrome and XLA.
    [Show full text]
  • Mitochondrial Carriers Regulating Insulin Secretion Profiled in Human Islets Upon Metabolic Stress
    Jiménez-Sánchez et al. Supplementary files Mitochondrial carriers regulating insulin secretion profiled in human islets upon metabolic stress Supplementary Table S1: Clinical Data of the human donors of pancreatic islets, type of analyses performed and tested conditions. Supplementary Table S2: Quantitative data related to the transcriptomic profiles of mitochondrial solute carriers and associated genes in human islets upon metabolic stress. NA: Not applicable, ND: not detected. Supplementary Table S3: Quantitative data related to the transcriptomic profiles of the electron transport chain machinery and related mitochondrial carriers in human islets upon metabolic stress.NA: Not applicable, ND: not detected. Supplementary Table S4: Quantitative data related to the transcriptomic profiles of the outer and inner mitochondrial membrane translocases TOM/TIM machinery in human islets upon metabolic stress.NA: Not applicable, ND: not detected. Supplementary Table S5: Quantitative data related to the transcriptomic profiles of mitochondrial iron transport genes in human islets under metabolic stress. NA: Not applicable, ND: not detected. Supplementary Table S6: Quantitative data related to the transcriptomic profiles of mitochondrial calcium transport genes in human islets upon metabolic stress. NA: Not applicable, ND: not detected. Supplementary Table S7: Primers used for quantitative RT-PCR analysis Supplementary Figure S1: Functional interaction network of human (a) mitochondrial calcium transport genes; (b) outer and inner mitochondrial membrane translocases TOM/TIM machinery; (c) electron transport chain machinery and related carriers; (d) mitochondrial iron transport genes. Nodes were connected using the STRING interaction knowledgebase with a confidence score >0.4. Supplementary Figure S2: Effects of high 25 mM glucose (G25) and 0.4 mM oleate (Olea) or palmitate (Palm) on the transcriptional regulation of the electron transport chain machinery.
    [Show full text]
  • Neurologic Outcomes in Friedreich Ataxia: Study of a Single-Site Cohort E415
    Volume 6, Number 3, June 2020 Neurology.org/NG A peer-reviewed clinical and translational neurology open access journal ARTICLE Neurologic outcomes in Friedreich ataxia: Study of a single-site cohort e415 ARTICLE Prevalence of RFC1-mediated spinocerebellar ataxia in a North American ataxia cohort e440 ARTICLE Mutations in the m-AAA proteases AFG3L2 and SPG7 are causing isolated dominant optic atrophy e428 ARTICLE Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy revisited: Genotype-phenotype correlations of all published cases e434 Academy Officers Neurology® is a registered trademark of the American Academy of Neurology (registration valid in the United States). James C. Stevens, MD, FAAN, President Neurology® Genetics (eISSN 2376-7839) is an open access journal published Orly Avitzur, MD, MBA, FAAN, President Elect online for the American Academy of Neurology, 201 Chicago Avenue, Ann H. Tilton, MD, FAAN, Vice President Minneapolis, MN 55415, by Wolters Kluwer Health, Inc. at 14700 Citicorp Drive, Bldg. 3, Hagerstown, MD 21742. Business offices are located at Two Carlayne E. Jackson, MD, FAAN, Secretary Commerce Square, 2001 Market Street, Philadelphia, PA 19103. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. Janis M. Miyasaki, MD, MEd, FRCPC, FAAN, Treasurer © 2020 American Academy of Neurology. Ralph L. Sacco, MD, MS, FAAN, Past President Neurology® Genetics is an official journal of the American Academy of Neurology. Journal website: Neurology.org/ng, AAN website: AAN.com CEO, American Academy of Neurology Copyright and Permission Information: Please go to the journal website (www.neurology.org/ng) and click the Permissions tab for the relevant Mary E.
    [Show full text]
  • Deafness-Dystonia-Optic Neuronopathy Syndrome
    Deafness-dystonia-optic neuronopathy syndrome Description Deafness-dystonia-optic neuronopathy (DDON) syndrome, also known as Mohr- Tranebjærg syndrome, is characterized by hearing loss that begins early in life, problems with movement, impaired vision, and behavior problems. This condition occurs almost exclusively in males. The first symptom of DDON syndrome is hearing loss caused by nerve damage in the inner ear (sensorineural hearing loss), which begins in early childhood. The hearing impairment worsens over time, and most affected individuals have profound hearing loss by age 10. People with DDON syndrome typically begin to develop problems with movement during their teens, although the onset of these symptoms varies among affected individuals. Some people experience involuntary tensing of the muscles (dystonia), while others have difficulty coordinating movements (ataxia). The problems with movement usually worsen over time. Individuals with DDON syndrome have normal vision during childhood, but they may develop vision problems due to breakdown of the nerves that carry information from the eyes to the brain (optic atrophy). Affected individuals can develop an increased sensitivity to light (photophobia) or other vision problems beginning in adolescence. Their sharpness of vision (visual acuity) slowly worsens, often leading to legal blindness in mid-adulthood. People with this condition may also have behavior problems, including changes in personality and aggressive or paranoid behaviors. They also usually develop a gradual decline in thinking and reasoning abilities (dementia) in their forties. The lifespan of individuals with DDON syndrome depends on the severity of the disorder. People with severe cases have survived into their teenage years, while those with milder cases have lived into their sixties.
    [Show full text]
  • Plasma Fatty Acid Ratios Affect Blood Gene Expression Profiles - a Cross-Sectional Study of the Norwegian Women and Cancer Post-Genome Cohort
    Plasma Fatty Acid Ratios Affect Blood Gene Expression Profiles - A Cross-Sectional Study of the Norwegian Women and Cancer Post-Genome Cohort Karina Standahl Olsen1*, Christopher Fenton2, Livar Frøyland3, Marit Waaseth4, Ruth H. Paulssen2, Eiliv Lund1 1 Department of Community Medicine, University of Tromsø, Tromsø, Norway, 2 Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, 3 National Institute of Nutrition and Seafood Research (NIFES), Bergen, Norway, 4 Department of Pharmacy, University of Tromsø, Tromsø, Norway Abstract High blood concentrations of n-6 fatty acids (FAs) relative to n-3 FAs may lead to a ‘‘physiological switch’’ towards permanent low-grade inflammation, potentially influencing the onset of cardiovascular and inflammatory diseases, as well as cancer. To explore the potential effects of FA ratios prior to disease onset, we measured blood gene expression profiles and plasma FA ratios (linoleic acid/alpha-linolenic acid, LA/ALA; arachidonic acid/eicosapentaenoic acid, AA/EPA; and total n-6/n-3) in a cross-section of middle-aged Norwegian women (n = 227). After arranging samples from the highest values to the lowest for all three FA ratios (LA/ALA, AA/EPA and total n-6/n-3), the highest and lowest deciles of samples were compared. Differences in gene expression profiles were assessed by single-gene and pathway-level analyses. The LA/ALA ratio had the largest impact on gene expression profiles, with 135 differentially expressed genes, followed by the total n-6/ n-3 ratio (125 genes) and the AA/EPA ratio (72 genes). All FA ratios were associated with genes related to immune processes, with a tendency for increased pro-inflammatory signaling in the highest FA ratio deciles.
    [Show full text]
  • Human CLPB) Is a Potent Mitochondrial Protein Disaggregase That Is Inactivated By
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.17.911016; this version posted January 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Skd3 (human CLPB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations Ryan R. Cupo1,2 and James Shorter1,2* 1Department of Biochemistry and Biophysics, 2Pharmacology Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, U.S.A. *Correspondence: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.01.17.911016; this version posted January 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Cells have evolved specialized protein disaggregases to reverse toxic protein aggregation and restore protein functionality. In nonmetazoan eukaryotes, the AAA+ disaggregase Hsp78 resolubilizes and reactivates proteins in mitochondria. Curiously, metazoa lack Hsp78. Hence, whether metazoan mitochondria reactivate aggregated proteins is unknown. Here, we establish that a mitochondrial AAA+ protein, Skd3 (human CLPB), couples ATP hydrolysis to protein disaggregation and reactivation. The Skd3 ankyrin-repeat domain combines with conserved AAA+ elements to enable stand-alone disaggregase activity. A mitochondrial inner-membrane protease, PARL, removes an autoinhibitory peptide from Skd3 to greatly enhance disaggregase activity. Indeed, PARL-activated Skd3 dissolves α-synuclein fibrils connected to Parkinson’s disease. Human cells lacking Skd3 exhibit reduced solubility of various mitochondrial proteins, including anti-apoptotic Hax1.
    [Show full text]
  • Nephritis Responses in Murine and Human Lupus Analysis Defines
    Downloaded from http://www.jimmunol.org/ by guest on October 2, 2021 is online at: average * The Journal of Immunology , 24 of which you can access for free at: 2012; 189:988-1001; Prepublished online 20 June from submission to initial decision 4 weeks from acceptance to publication Celine C. Berthier, Ramalingam Bethunaickan, Tania Gonzalez-Rivera, Viji Nair, Meera Ramanujam, Weijia Zhang, Erwin P. Bottinger, Stephan Segerer, Maja Lindenmeyer, Clemens D. Cohen, Anne Davidson and Matthias Kretzler 2012; doi: 10.4049/jimmunol.1103031 http://www.jimmunol.org/content/189/2/988 Cross-Species Transcriptional Network Analysis Defines Shared Inflammatory Responses in Murine and Human Lupus Nephritis J Immunol cites 60 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/189/2/988.full#ref-list-1 http://www.jimmunol.org/content/suppl/2012/06/20/jimmunol.110303 1.DC1 This article Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of October 2, 2021. The Journal of Immunology Cross-Species Transcriptional Network Analysis Defines Shared Inflammatory Responses in Murine and Human Lupus Nephritis Celine C.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • WO 2016/040794 Al 17 March 2016 (17.03.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/040794 Al 17 March 2016 (17.03.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12N 1/19 (2006.01) C12Q 1/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C12N 15/81 (2006.01) C07K 14/47 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/049674 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 11 September 2015 ( 11.09.201 5) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/050,045 12 September 2014 (12.09.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: WHITEHEAD INSTITUTE FOR BIOMED¬ DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, ICAL RESEARCH [US/US]; Nine Cambridge Center, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Cambridge, Massachusetts 02142-1479 (US).
    [Show full text]